Neurogene (NGNE) news
Recent news
Neurogene Inc: Canaccord Genuity cuts target price to $166 from $180
AInvest Wire · Aug 11, 2026Neurogene Q2 EPS USD -1.53 (removes extraneous word)
Neurogene Inc. (NASDAQ: NGNE) is expected to report its second-quarter 2026 earnings on August 7, 2026, with an estimated EPS of -1.42 USD . Analysts project a continuation of the company’s trend of negative earnings, with the EPS estimate for Q2 2026 slightly worse than the -1.39 USD reported in…
AInvest Wire · Aug 11, 2026Neurogene Q2 adjusted EPS USD -1.53 vs. IBES estimate USD -1.42
Neurogene Inc (NGNE) reported Q2 2026 adjusted earnings per share (EPS) of -$1.53, falling short of the IBES estimate of -$1.42 . The results indicate continued financial challenges for the company, which has consistently posted negative EPS in recent quarters. For context, NGNE’s Q1 2026 EPS was…
AInvest Wire · Aug 11, 2026Neurogene announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jul 6, 2026Neurogene offer prices at $30.00/share
AInvest Wire · Jul 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.